COVID-19 Vaccine Before ICI Initiation Tied to Increased Survival in Patients With Cancer
For patients with certain types of advanced lung or skin cancer, administration of SARS-CoV-2 mRNA vaccine within 100 days of starting immune checkpoint inhibitors is associated with increased overall survival.
A study presented at the annual meeting of the European Society for Medical Oncology found that patients with non-small cell lung cancer (NSCLC) and melanoma treated with ICIs had increased overall survival when administered the SARS-CoV-2 mRNA vaccine.
- Researchers from the University of Texas MD Anderson Cancer Center extracted data for patients with NSCLC and melanoma.
- The study examined whether mRNA vaccines targeting nontumor antigens would sensitize tumors to ICIs.
No direct quote available in the text.
Author's summary: COVID-19 vaccine increases survival in cancer patients.
More News
- Sinners: blood, blues and vampires - The Stute
- Sennheiser HDB 630 vs. Momentum 4: Premium Wireless Headphones Compared
- Wrexham 3-2 Coventry: Report, result, goals in Championship
- The Constitution Leaves No Room for Self-Serving “Insertions” | The Zimbabwe Mail
- Adobe’s experimental AI tool can edit entire videos using one frame
- The power of organising and how to win the outsourcing battle | Article | News | UNISON National
- Alito’s Oil Investments Pollute Contractor Accountability Case